Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

ogical and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise. SOURCE Omeros Corporation


'/>"/>
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
(Date:10/22/2014)... Oct. 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) ... million people worldwide are living with diabetes, with  that ... 2030.  The global market for diabetes treatments is approximately ... people worldwide died from pancreatic cancer.  Pancreatic cancer is ... cancer in the United States , ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... NEW HAVEN, Conn., Dec. 8, 2011  Cenestra Health announces ... has issued a new U.S. patent, No. 8,071,646 (the ... for highly pure formulations of eicosapentaenoic acid (EPA) and ... to about 5:1.  The ,646 patent provides exclusivity for ...
... team of scientists, led by Guillaume Gervais from McGill,s ... has engineered one of the world,s smallest electronic circuits. ... about 150 atoms or 15 nanometers (nm). This discovery, ... have a significant effect on the speed and power ...
... 2011  Fortis now offers a Bachelor of Science ... campuses – Fortis College, Cutler Bay and Fortis College, ... to students who already have a bachelor, associate or ... Fortis is now enrolling candidates who wish ...
Cached Biology Technology:Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 2Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 3Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students 2Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students 3
(Date:10/22/2014)... identity analyst firm Acuity Market Intelligence forecasts that in ... have a chip-based National eID card, including near-complete regional ... Asia , with its vast population, is expected ... of all National eID cards issued between 2014 and ... National eID Industry Report: 2014 Edition" — projects ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... Curabitur molestie mauris sed dolor dictum iaculis. Nulla ... in condimentum tincidunt, nisl lacus porta diam, sit amet suscipit ... consectetur adipiscing elit. Mauris est velit, iaculis scelerisque tempus semper, ... nec ut erat. Donec fringilla dapibus pharetra. Etiam vitae mi ...
... Oct. 16, 2012  Today 23andMe, the leading personal ... as Vice President Communications, Neil Rothstein as Vice ... Strategic Alliances joining the company,s executive leadership team. ... Castro is responsible for the company,s corporate communications, ...
... 17, 2012 Rising crime rates and terrorism ... monitoring and introduce reliable border control systems. These ... identification and automated immigration at all entry points, ... in the government vertical across Asia-Pacific. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: